User:Mr. Ibrahem/Beractant
| Clinical data | |
|---|---|
| Trade names | Survanta, Alveofact |
| AHFS/Drugs.com | Monograph |
| Routes of administration | In the trachea[1] |
| Drug class | Pulmonary surfactant[1] |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Onset of action | Within minutes[1] |
| Duration of action | 2 to 3 days[1] |
  (what is this?) (verify) | |
Beractant, sold under the brand name Survanta, is a medication used to prevent and treat respiratory distress syndrome in newborns.[1] Specifically it is used in those who are born premature.[1] It is given in the trachea.[1] Effects begin within minutes and may last for up to 3 days.[1]
Common side effects include slow heart rate, low oxygen, low blood pressure, high blood pressure, apnea, and blockage of the endotracheal tube.[1] Other side effects may include sepsis.[1] It is a pulmonary surfactant derived from cows.[1]
Beractant was approved for medical use in the United States in 1991.[1] In the United States 100 mg costs about 400 USD as of 2022.[2]
References[edit]
- ^ a b c d e f g h i j k l m n o "Beractant Monograph for Professionals". Drugs.com. Archived from the original on 25 January 2021. Retrieved 10 January 2022.
- ^ "Survanta Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 19 January 2021. Retrieved 10 January 2022.